Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed FinancingPRNewsWire · 4 days ago
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant InducementPRNewsWire · Oct 16, 2026
Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant InducementPRNewsWire · Oct 14, 2026
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing AgreementPRNewsWire · Oct 13, 2026
Scinai Regains Compliance with Nasdaq Minimum Bid Price RequirementPRNewsWire · Sep 21, 2026
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO BusinessPRNewsWire · Sep 8, 2026Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen.